Welcome to our dedicated page for Bio-Rad Laboratories news (Ticker: BIO), a resource for investors and traders seeking the latest updates and insights on Bio-Rad Laboratories stock.
Bio-Rad Laboratories, Inc. (NYSE: BIO) is a global leader in providing innovative tools and services to the life science research and clinical diagnostics markets. Established in 1952 and headquartered in Hercules, California, Bio-Rad boasts a robust network of operations spanning the globe, supported by a dedicated team of over 7,600 employees.
Bio-Rad's core business is segmented into two main areas: Clinical Diagnostics and Life Sciences. In the Clinical Diagnostics segment, which contributes to 56% of the company’s sales, Bio-Rad offers a range of test systems and specialized quality controls designed to ensure the accuracy and reliability of clinical laboratory results. These products play a critical role in patient care, enabling healthcare providers to make informed decisions.
The Life Sciences segment, accounting for 44% of sales, focuses on developing and manufacturing instruments and reagents used in research, biopharmaceutical production, and food testing. Bio-Rad is also a market leader in digital PCR (dPCR) technology, which is pivotal in genomics, proteomics, and drug discovery research.
Bio-Rad serves over 100,000 research and industry customers worldwide, fostering significant advancements in scientific research and development. The company has built strong partnerships and customer relationships that drive the introduction of new technologies in fields such as genomics, proteomics, drug discovery, food safety, and medical diagnostics.
Geographically, Bio-Rad's revenue distribution is diversified with 42% of sales from the Americas, 31% from Europe, 31% from Asia, and 6% from other regions, highlighting its extensive global reach.
One notable aspect of Bio-Rad's portfolio is its 33% ownership in Sartorius, a leading supplier of laboratory and bioprocessing solutions. Sartorius specializes in single-use technology for biologics manufacturing, thereby complementing Bio-Rad's offerings and enhancing its presence in the biopharmaceutical market.
With a strong legacy of innovation and a commitment to advancing scientific and medical research, Bio-Rad continues to lead in delivering high-quality, reliable solutions to its customers.
Bio-Rad Laboratories, Inc. (NYSE: BIO.B) will release its first-quarter 2023 financial results on May 4, 2023, after market close. A conference call is scheduled for 2 PM Pacific Time to discuss these results, with participation details available. Bio-Rad is recognized as a leader in life science research and clinical diagnostics, with a revenue of $2.8 billion in 2022. The company serves a wide range of customers including universities, hospitals, and biotech firms globally. For more information, the company’s Investor Relations section offers access to the webcast of the call. This will provide insights into the company’s performance and strategic direction as it progresses through the fiscal year.
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B) announced its participation in a fireside chat at Citi’s 2023 Healthcare Services, MedTech, Tools & HCIT Conference. The event is scheduled for Thursday, March 2, 2023, at 11:45 AM Eastern Time (8:45 AM Pacific Time). A live webcast and replay will be available on the Investor Relations section of Bio-Rad's website. With over 70 years of expertise, Bio-Rad leads in life science research and clinical diagnostics, serving various sectors including healthcare and biotechnology. The company had approximately $2.8 billion in revenues in 2022, employing around 8,300 staff worldwide.
Bio-Rad Laboratories (BIO, BIOb) reported Q4 2022 net sales of $730.3 million, down 0.3% from Q4 2021, primarily due to a significant drop in COVID-related revenue. Life Science sales rose 10.1%, while Clinical Diagnostics declined 8.7%. Net income surged to $827.7 million, or $27.78 per share, from a net loss of $1.57 billion in Q4 2021, driven by fair market value changes in equity securities. For FY 2022, total sales decreased 4.1% to $2.8 billion, with a net loss of $3.63 billion. The company projects 6-7% non-GAAP currency-neutral revenue growth in 2023, citing a strong market recovery and operational improvements.
Element Biosciences and Bio-Rad Laboratories have announced a partnership to advance RNA sequencing through the integration of Bio-Rad's SEQuoia RNA Sequencing Library Preparation portfolio with Element's AVITI™ Benchtop Sequencer. This collaboration aims to enhance RNA sequencing accuracy and efficiency, utilizing SEQuoia kits designed for various RNA inputs. The AVITI System offers unique capabilities, including two independent flow cells and up to 2 billion reads, ensuring high-quality data. Results from their collaboration will be presented at the AGBT General Meeting on February 9, 2023. This initiative positions both companies to deliver a cost-effective solution for genomic research.
Bio-Rad Laboratories, Inc. will report its financial results for Q4 and full year 2022 on February 16, 2023, post-market close. Management will host a conference call at 2 PM PT (5 PM ET) to discuss these results. Participants can dial 844-200-6205 in the U.S. or +1 929-526-1599 internationally, using access code: 143970. A live webcast will also be available on their website. Bio-Rad is recognized globally for developing and marketing life science and clinical diagnostic products, generating $2.9 billion in revenues as of 2021.
Bio-Rad Laboratories will present at the 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023, at 4:30 p.m. Pacific Time. CEO Norman Schwartz will lead the company overview, followed by a Q&A with Andrew Last and Ilan Daskal, Bio-Rad's Executive Vice Presidents. The event will be available via a webcast on Bio-Rad's website.
Bio-Rad Laboratories (NYSE: BIO and BIO.B) announced that its management will participate in a Fireside Chat during the Credit Suisse 31st Annual Healthcare Conference on Tuesday, November 8, 2022, at 11:00 AM (PST). A live webcast will be accessible on the company's Investor Relations webpage at bio-rad.com. Bio-Rad, based in Hercules, California, is a leader in life science research and clinical diagnostics, with approximately 8,200 employees and $2.9 billion in revenue for 2021.
Bio-Rad Laboratories reported Q3 2022 net sales of $680.8 million, down 8.9% from Q3 2021. COVID-related revenue declined to $17 million from $57 million in the previous year. The Life Science segment saw a 14.9% decrease in net sales, while Clinical Diagnostics dipped 2.8%. The company posted a net loss of $164.2 million, or $5.52 per share, compared to net income of $3.9 billion or $129.96 per share in Q3 2021. The non-GAAP outlook for 2022 anticipates currency-neutral revenue growth at the high end of 1-2% guidance.
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) will report its third-quarter 2022 financial results on October 27, 2022, after market close. A conference call discussing these results is scheduled for 2 PM Pacific Time the same day. Bio-Rad, a leader in life science research and clinical diagnostics, generated $2.9 billion in revenues for 2021 and employs approximately 7,900 individuals worldwide. Investors can access a live webcast via the 'Investor Relations' section of the company's website.
Bio-Rad Laboratories (NYSE: BIO) has announced the acquisition of Curiosity Diagnostics for up to $170 million, comprising $100 million in cash and $70 million in future milestones. Curiosity, based in Poland, is developing a rapid diagnostics PCR system for the molecular diagnostics market. This acquisition aims to enhance Bio-Rad's Clinical Diagnostics Group, expanding into near-patient molecular diagnostics. With Bio-Rad's extensive market presence and Curiosity's innovative technology, the deal is anticipated to improve product offerings and market reach.
FAQ
What is the current stock price of Bio-Rad Laboratories (BIO)?
What is the market cap of Bio-Rad Laboratories (BIO)?
What does Bio-Rad Laboratories, Inc. specialize in?
When was Bio-Rad Laboratories founded?
Where is Bio-Rad Laboratories headquartered?
What are the core business segments of Bio-Rad?
What percentage of Bio-Rad's sales come from the Clinical Diagnostics segment?
How many employees does Bio-Rad have?
What is Bio-Rad's involvement in the biopharmaceutical industry?
What is Bio-Rad's market reach?
What is the significance of Bio-Rad's ownership in Sartorius?
How does Bio-Rad contribute to scientific research and development?
